Home » Stocks » EQ

Equillium, Inc. (EQ)

Stock Price: $4.93 USD -0.11 (-2.18%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $4.99 +0.06 (1.22%) Dec 3, 7:46 PM

Stock Price Chart

Key Info

Market Cap 121.91M
Revenue (ttm) n/a
Net Income (ttm) -28.46M
Shares Out 21.37M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $4.93
Previous Close $5.04
Change ($) -0.11
Change (%) -2.18%
Day's Open 5.03
Day's Range 4.85 - 5.05
Day's Volume 338,550
52-Week Range 2.30 - 26.50

More Stats

Market Cap 121.91M
Enterprise Value 41.25M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.37M
Float n/a
EPS (basic) -1.56
EPS (diluted) -1.54
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 684,913
Short Ratio 0.24
Short % of Float n/a
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.55
Revenue n/a
Operating Income -28.19M
Net Income -28.46M
Free Cash Flow -25.59M
Net Cash 80.66M
Net Cash / Share 3.26
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.68%
ROE -44.79%
ROIC -69.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(280.32% upside)
Current: $4.93
Target: 18.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.73-8.62
Net Income-25.60-13.25
Shares Outstanding17.3812.19
Earnings Per Share-1.47-1.09
Operating Cash Flow-22.95-7.53
Capital Expenditures-0.07-0.04
Free Cash Flow-23.02-7.56
Cash & Equivalents53.1465.91
Total Debt9.68-
Net Cash / Debt43.4665.91
Book Value41.8564.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Equillium, Inc.
Country United States
Employees 26
CEO Bruce Steel

Stock Information

Ticker Symbol EQ
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EQ
IPO Date October 11, 2018


Equillium, a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.